Why do we not have a precise answer to the question of which patients with pulmonary
embolism (PE), particularly intermediate risk (submassive) PE, ought to receive fibrinolysis …

We fully agree with Drs. Güner, Kahraman, and Ertürk that full-dose fibrinolytic therapy is a
“double-edged sword” in the treatment of acute pulmonary embolism (PE), 1 mostly due to …

Controversy over the role of fibrinolysis in patients with intermediate-risk pulmonary
embolism (PE) has persisted because of the lack of adequately sized trials. The PEITHO …

Background Improved prediction of the risk of major bleeding in patients with acute
pulmonary embolism (PE) receiving systemic thrombolysis is crucial to guide the choice of …

Background Benefit of thrombolytic therapy in patients with massive pulmonary embolism
(PE) is evident. However, evidence supporting benefit in clinical outcomes of this approach …

Morbidity and mortality associated with acute pulmonary embolism (PE) remain high despite
recent advances in diagnosis and treatment. The annual incidence of the disease ranges …

Background The role of thrombolytic agents in the treatment of pulmonary thromboembolism
(PTE) remains a controversial issue. The objective of this study is to assess the efficacy and …

Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

Objective To explore the comparative clinical efficacy and safety outcomes of
anticoagulation before (pre-) or following (post-) thrombolytic therapy in systemic …

We have recently read with great interest the article by Sanchez et al entitled “Reduced-
dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism …